| Literature DB >> 34007147 |
Abdulaziz A Al Taisan1,2, Abdulaziz A Alshamrani1, Abdullah T AlZahrani3, Abdulelah A Al-Abdullah1.
Abstract
PURPOSE: To evaluate the outcome of pars plana vitrectomy (PPV) and combined pars plana vitrectomy with scleral buckle (PPV-SB) in the primary pediatrics rhegmatogenous retinal detachment repair.Entities:
Keywords: pars plana vitrectomy; pediatrics; retinal detachment; scleral buckle
Year: 2021 PMID: 34007147 PMCID: PMC8121681 DOI: 10.2147/OPTH.S305910
Source DB: PubMed Journal: Clin Ophthalmol ISSN: 1177-5467
Baseline Characteristics of Our Cohort of 117 Patients (122 Eyes)
| PPVa (n=80) | PPV-SBb (n=42) | |||
|---|---|---|---|---|
| Age (years) | Mean (SD) | 10.2 (5.3) | 10.9 (4.8) | 0.633 |
| Gender | Male | 56 (70) | 30 (71.4) | 0.869 |
| Female | 24 (31.2) | 12 (30) | ||
| Onset | Acute | 58 (72.5) | 11 (26.2) | <0.001 |
| Chronic | 22 (27.5) | 31 (73.8) | ||
| Macula | On | 6 (7.5) | 2 (4.8) | 0.713 |
| Off | 74 (92.5) | 40 (95.2) | ||
| Eye involved | OD | 38 (47.5) | 18 (42.9) | 0.625 |
| Etiology | Spontaneous | 5 (6.3) | 3 (7.1) | 0.7 |
| Traumatic | 36 (45) | 14 (33.3) | 0.25 | |
| High myopia | 10 (12.5) | 8 (19) | 0.33 | |
| Post surgery | 22 (27.5) | 5 (11.9) | 0.05 | |
| Syndrome | 7 (8.8) | 12 (28.6) | 0.004 | |
| Marfan | 2 | 2 | ||
| Knoblock | 2 | 1 | ||
| Down | 0 | 2 | ||
| Albinism | 1 | 0 | ||
| Stickler | 1 | 4 | ||
| Neurofibromatosis | 1 | 0 | ||
| Microphthalmos | 0 | 1 | ||
| Pierson | 0 | 1 |
Notes: aPars plana vitrectomy. bCombined pars plana vitrectomy with scleral buckle.
Intraoperative Findings for Both Groups PPV and PPV/SB
| PPV n (%) | PPV/SB n (%) | |||
|---|---|---|---|---|
| Intraoperative breaks | Single | 26 (32.5) | 10 (23.8) | 0.739 |
| Multiple | 30 (37.5) | 16 (38.1) | ||
| GRT | 12 (15) | 8 (19) | ||
| No breaks seen | 12 (15) | 8 (19) | ||
| Location of breaks | Inferior | 18 (23) | 15 (36) | 0.036 |
| Noninferior | 62 (77) | 27 (64) | ||
| Quadrant involved | Total | 45 (56.3) | 27 (64.3) | 0.391 |
| Sub-total | 35 (43.8) | 15 (35.7) | ||
| Lens status | Aphakia/pseudophakia | 11 (13.8) | 3 (7.1) | 0.28 |
| Phakia | 69 (86.3) | 39 (92.9) | ||
| FTMH | Yes | 5 (6.3) | 3 (7.1) | 0.850 |
| No | 75 (93.8) | 39 (92.9) | ||
| Presence of PVR | Absent | 59 (73.8) | 19 (45.2) | 0.002 |
| Present | 21 (26.3) | 23 (54.8) | ||
| Retinectomy | Yes | 10 (12.5) | 4 (9.5) | 0.769 |
| No | 70 (87.5) | 38 (90.5) | ||
| Intentional retinotomy | Yes | 19 (23.8) | 10 (23.8) | 0.994 |
| No | 61 (76.3) | 32 (76.2) | ||
| Dye used | Brilliant blue (with or without triamcinolone) | 16 (20) | 4 (9.5) | |
| Triamcinolone alone | 26 (32.5) | 21 (50) | ||
| No dye | 38 (47.5) | 17 (40.5) | ||
| Tamponade agents | Gas (SF6 or C3F8) | 9 (11.3) | 2 (4.8) | 0.670 |
| Silicone oil | 71 (88.8) | 40 (95.2) | ||
| Surgeon | Fellow | 14 (17.5) | 7 (16.7) | 0.908 |
| Consultant | 66 (82.5) | 35 (83.3) |
Abbreviations: GRT, giant retinal tear; FTMH, full-thickness macular hole; PVR, proliferate vitreoretinopathy, SF6, sulfur hexafluoride; C3F8 perfluoropropane.
Single Surgery Success Rates According to Chronicity, Status of PVR and Etiology
| PPV | PPV/SB | ||
|---|---|---|---|
| SSSR/Total (%) | SSSR/Total (%) | ||
| Overall SSSR | 61/80 (76.3) | 28/42 (66.7) | 0.45 |
| Acute RRD | 45/58(77.5) | 7/11 (63.6) | 0.78 |
| Chronic RRD | 16/22 (72.7) | 21/31 (67.6) | |
| PVR+ | 17/21 (81) | 18/23 (78.3) | 0.99 |
| PVR– | 44/59 (74.6) | 10/19 (52.6) | |
| Spontaneous RRD | 5/5 (100) | 3/3 (100) | 1.0 |
| Traumatic | 26/36 (72.2) | 9/14 (64.3) | 0.73 |
| High myopia | 8/10 (80) | 5/8 (62.5) | 0.61 |
| Post surgery | 15/22 (61.3) | 3/5 (60) | 0.99 |
| Syndromatic | 7/7 (100) | 8/12 (66.7) | 0.25 |
Abbreviations: PVR, proliferative vitreoretinopathy; SSSR, single surgery success rate. RRD, hegmatogenous retinal detachment.
Number of Reattachment Surgeries and the Success Rate
| No. of Reattachment Surgeries | PPV n (%) | PPV-SB n (%) |
|---|---|---|
| 1 | 61 (76.3) | 28 (66.7) |
| 2 | 14 (17.5) | 11 (26) |
| 3 | 2 (4) | 3 (7.1) |
| 4 | 1 (1.3) | 0 |
Initial and Final BCVA in PPV and PPV-SB Groups
| Initial BCVA n (%) | Final BCVA n (%) | P value | |
|---|---|---|---|
| 20/20 to 20/40 | 3 (3.8) | 6 (7.5) | 0.019 |
| 24/40 to 20/200 | 13 (16.3) | 21 (26.3) | |
| Less than 20/200 | 50 (62.5) | 41 (51.3) | |
| NAa | 14 (17.5) | 12 (15) | |
| 20/20 to 20/40 | 1 (2.4) | 1 (2.4) | 0.004 |
| 24/40 to 20/200 | 3 (7.1) | 16 (38.1) | |
| Less than 20/200 | 30 (71.4) | 17 (40.5) | |
| NAb | 14 (17.5) | 8 (19) | |
| 0.021 | 0.27 |
Note: aNot available or could not be obtained.
Abbreviation: BCVA, best corrected visual acuity.
Rate of Postoperative Complications
| Complications | 6 Months | 12 Months | Last Visit | |||
|---|---|---|---|---|---|---|
| PPV | PPV/SB | PPV | PPV/SB | PPV | PPV/SB | |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| ERM | 7 (8.8) | 2 (4.8) | 2 (2.5) | 3 (7.1) | 5 (6.3) | 2 (4.8) |
| Macular hole | 1 (1.3) | 0 | 1 (1.3) | 0 | 1 (1.3) | 0 |
| Cataract | 12 (15) | 11 (26.2) | 7 (8.8) | 9 (21.4) | 6 (7.5) | 5 (11.9) |
| High IOP | 7 (8.8) | 2 (4.8) | 11 (13.8) | 6 (14.3) | 12 (15) | 5 (11.9) |
| PCO | 0 | 1 (2.4) | 0 | 0 | 0 | 0 |
| Band keratopathy | 1 (1.3) | 2 (4.8) | 2 (2.5) | 3 (7.1) | 3 (3.8) | 1 (2.4) |
| Phthisis bulbi | 0 | 0 | 1 (1.3) | 0 | 1 (1.3) | 0 |
| PVR | 3 (3.8) | 2 (4.8) | 1 (1.3) | 1 (2.4) | 0 | 0 |
| Total no. of eyesa | 27 (33.8) | 18 (42.9) | 27 (33.8) | 19 (45.2) | 26 (32.5) | 13 (31) |
Notes: aSome eyes developed more than one complication.
Abbreviations: ERM, epiretinal membrane; IOP, intraocular pressure; PCO, posterior capsular opacification; PVR, proliferative vitreoretinopathy.